Ionis Pharmaceuticals, Inc.
IONS
$81.84
$0.530.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -65.33% | 243.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -65.33% | 243.47% | |||
| Cost of Revenue | -0.69% | 13.69% | |||
| Gross Profit | -127.50% | 463.98% | |||
| SG&A Expenses | 6.83% | 8.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.50% | 12.12% | |||
| Operating Income | -214.57% | 195.20% | |||
| Income Before Tax | -203.94% | 184.14% | |||
| Income Tax Expenses | 1,165.00% | -117.24% | |||
| Earnings from Continuing Operations | -204.09% | 184.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -204.09% | 184.08% | |||
| EBIT | -214.57% | 195.20% | |||
| EBITDA | -210.25% | 199.05% | |||
| EPS Basic | -203.68% | 183.87% | |||
| Normalized Basic EPS | -211.16% | 197.81% | |||
| EPS Diluted | -215.00% | 175.62% | |||
| Normalized Diluted EPS | -227.38% | 185.36% | |||
| Average Basic Shares Outstanding | 0.39% | 0.25% | |||
| Average Diluted Shares Outstanding | -12.38% | 14.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||